Sign In
Buy MBRX
$0.400
-0.620 (-60.78%)
At Close: Jul 31, 2026
Moleculin Announces Preclinical Data Confirms Efficacy of Annamycin in Lung Metastases
11:30am, Thursday, 25'th Jun 2020
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses,
Virtual Conference for Life Sciences Companies Broadcast Live June 25, 2020
12:49pm, Tuesday, 23'rd Jun 2020
NEW YORK, June 23, 2020 -- Life Sciences Investor Forum today announced the agenda for its second quarterly event for public and private companies, investors and industry.
Moleculin to Present at the Life Sciences Investor Forum
11:30am, Tuesday, 23'rd Jun 2020
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today annou
Virtual Conference for Life Sciences Companies Broadcast Live June 25, 2020
12:00am, Tuesday, 23'rd Jun 2020
Company executives will share corporate vision and answer audience questions at LifeSciencesInvestorForum.com
WPD Pharmaceuticals : Licensor Announces Confirmatory in Vitro Analysis of WP1122 | MarketScreener
11:01am, Monday, 22'nd Jun 2020Is Moleculin Biotech (MBRX) Stock Outpacing Its Medical Peers This Year?
03:30pm, Wednesday, 17'th Jun 2020
Is (MBRX) Outperforming Other Medical Stocks This Year?
Moleculin Announces Confirmatory In Vitro Analysis of WP1122
11:30am, Tuesday, 16'th Jun 2020
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that a repeat of previous in
Moleculin Biotech (NASDAQ:MBRX) Coverage Initiated by Analysts at Maxim Group
03:38am, Wednesday, 10'th Jun 2020
Equities research analysts at Maxim Group began coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a report issued on Tuesday, TipRanks reports. The brokerage set a “buy” rating and a $3.00
Moleculin Announces Submission to Expand Clinical Sites in European AML Trial
11:30am, Thursday, 04'th Jun 2020
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that it has submitted request
Moleculin Announces Emory University Clinical Trial of WP1066 Begins Enrollment
11:30am, Tuesday, 02'nd Jun 2020
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that recruiting has begun and
Is Moleculin Biotech (MBRX) Stock Outpacing Its Medical Peers This Year?
03:30pm, Monday, 01'st Jun 2020
Is (MBRX) Outperforming Other Medical Stocks This Year?
Moleculin Announces Common Stock Will Resume Trading on the NASDAQ on May 28, 2020
09:55pm, Wednesday, 27'th May 2020
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses,
Nasdaq Scheduled Resumption in Moleculin Biotech, Inc.
08:45pm, Wednesday, 27'th May 2020
NEW YORK, May 27, 2020 -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading in Moleculin Biotech, Inc. (Nasdaq: MBRX) is scheduled to resume on Thursday, May 28,.
Moleculin Provides Update on Coronavirus Drug Development
08:05pm, Wednesday, 27'th May 2020
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses,
Moderna COVID-19 vaccine data is ‘baby-step’ in right direction: Expert
06:47pm, Monday, 18'th May 2020
Professor of Medicine at Yale and Director of The Yale New Haven Hospital Center for Outcomes Research and Evaluation Dr. Harlan Krumholz joins Yahoo Finance’s Seana Smith to discuss Moderna’s rec
